Pharmaceutical News

RSS

Influenza and pneumococcal vaccines together appear to increase risk of fever in children

Giving young children the influenza and pneumococcal vaccines together appears to increase their risk of fever, according to a study led by researchers from Columbia University Medical Center (CUMC) and the Centers for Disease Control and Prevention (CDC). However, the fever was brief, and medical care was sought for few children, supporting the routine immunization schedule for these vaccines, including the recommendation to administer them simultaneously.

6 Jan 2014

UVA team works with local rescue squads to diagnose stroke patients before they reach hospital

A University of Virginia Health System team is working with local rescue squads to diagnose stroke patients before they reach the hospital, enabling more patients to receive lifesaving treatment and have a full recovery.

6 Jan 2014

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal Pharmaceuticals LLC today announced the launch of generic Esomeprazole strontium delayed-release capsules 49.3 mg. This new esomeprazole therapy is the generic equivalent of the recently launched brand Esomeprazole strontium. It contains the same active moiety (esomeprazole) in a different salt form as found in the leading PPI brand Nexium (esomeprazole magnesium) and presents a potentially more affordable treatment option for GERD in adult patients.

6 Jan 2014

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.

6 Jan 2014

Adherence to nutrition recommendations is weak among people with metabolic syndrome

Adherence to dietary recommendations is weak among people suffering from metabolic syndrome or having increased risk for metabolic syndrome, according to the Nordic SYSDIET study led by the University of Eastern Finland.

6 Jan 2014

Jones Engineering Group to focus on pharmaceutical industries in Saudi Arabia

Jones Engineering Group is continuing to develop its presence in Saudi Arabia with a strategic focus on the food and beverage, pharmaceutical and health care industries. The leading international engineering contracting group has recently signed a deal with a major multinational FMCG client worth an estimated €20 million. Work on the project will commence immediately.

6 Jan 2014

RegeneRx's Tβ4 gets FDA Orphan Drug designation for treatment of Neurotrophic Keratopathy

RegeneRx Biopharmaceuticals, Inc. announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development for its drug candidate, Thymosin beta 4 (Tβ4), for the treatment of Neurotrophic Keratopathy, a serious degenerative disease of the corneal epithelium (the outside layer of the eye).

5 Jan 2014

NPS Pharmaceuticals' Natpara gets orphan drug designation for treatment of hypoparathyroidism

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.

3 Jan 2014

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc., a privately-held biotechnology company pioneering microRNA replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology.

3 Jan 2014

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Probiodrug AG announced today the transfer of its experimental cyclin-dependent kinase 9 inhibitor program to AstraZeneca. The transaction includes the sale to AstraZeneca of a lead molecule and back-up compounds with the associated intellectual property. CDK9, which has been implicated in the transcriptional regulation of genes involved in proliferation and inflammation, is a promising target for the treatment of both cancer and inflammatory diseases.

3 Jan 2014

Chinese herbal medicine effective at alleviating acute inflammatory and nerve pain

A compound derived from a traditional Chinese herbal medicine has been found effective at alleviating pain, pointing the way to a new nonaddictive analgesic for acute inflammatory and nerve pain, according to UC Irvine pharmacology researchers.

3 Jan 2014

Opioid receptor-triggered spinal mTORC1 activation contributes to morphine tolerance, hyperalgesia

Currently, opioids are the standard treatment for chronic pain. Patients on opioids for long periods of time become desensitized to these drugs or become paradoxically hypersensitive to pain (hyperalgesia); however, the adaptive mechanisms are not well understood.

3 Jan 2014

Youngevity International launches advanced anti-aging supplement

Youngevity International, Inc., a global direct marketer of nutritional and lifestyle products and also a vertically-integrated producer of gourmet coffees for the commercial, retail and direct sales channels, announces the launch of an advanced anti-aging supplement, Imortalium into our global direct sales channel.

2 Jan 2014

Most clinical trials of vitamin supplements have flawed methodology

Most large, clinical trials of vitamin supplements, including some that have concluded they are of no value or even harmful, have a flawed methodology that renders them largely useless in determining the real value of these micronutrients, a new analysis suggests.

31 Dec 2013

GRADE study evaluates four new medications for Type 2 diabetes

The GRADE study at the University of Alabama at Birmingham had a special visitor in November. Red suit. Black boots. White beard. Belly that shook like a bowl full of jelly. A V.I.E. (Very Important Elf) visited this national clinical trial for Type 2 diabetes.

31 Dec 2013

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.

30 Dec 2013

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

BioCryst Pharmaceuticals, Inc. today announced that the National Institute of Allergy and Infectious Diseases has exercised an option to conduct the investigational new drug enabling program and to submit an IND.

30 Dec 2013

Veloxis Pharmaceuticals seeks FDA approval to market Envarsus for prevention of organ rejection

Veloxis Pharmaceuticals A/S, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Envarsus (formerly LCP-Tacro) for the prevention of organ rejection in kidney transplant recipients.

30 Dec 2013

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Genzyme, a Sanofi company, announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.

30 Dec 2013

MitoQ antioxidant reverses MS-like disease in animal

Researchers at Oregon Health & Science University have discovered that an antioxidant designed more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like disease.

27 Dec 2013

Pharmaceutical News

Influenza and pneumococcal vaccines together appear to increase risk of fever in children

UVA team works with local rescue squads to diagnose stroke patients before they reach hospital

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

Adherence to nutrition recommendations is weak among people with metabolic syndrome

Jones Engineering Group to focus on pharmaceutical industries in Saudi Arabia

RegeneRx's Tβ4 gets FDA Orphan Drug designation for treatment of Neurotrophic Keratopathy

NPS Pharmaceuticals' Natpara gets orphan drug designation for treatment of hypoparathyroidism

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Chinese herbal medicine effective at alleviating acute inflammatory and nerve pain

Opioid receptor-triggered spinal mTORC1 activation contributes to morphine tolerance, hyperalgesia

Youngevity International launches advanced anti-aging supplement

Most clinical trials of vitamin supplements have flawed methodology

GRADE study evaluates four new medications for Type 2 diabetes

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

Veloxis Pharmaceuticals seeks FDA approval to market Envarsus for prevention of organ rejection

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

MitoQ antioxidant reverses MS-like disease in animal

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News